## IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A method of treating or preventing at least one disease selected from the group consisting of type II diabetes type II,or obesity, and appetite regulation, in a subject in need thereofof treatment, comprising administering at least one aryl dicarboxamide of formula (I):

$$\begin{array}{c|c}
R^{4} & \\
R^{1} & \\
R^{2} & \\
Cy & O
\end{array}$$

as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts thereof, wherein:

A is an aminocarbonyl moiety of the formula -CO-NHR<sup>6</sup>, wherein R<sup>6</sup> is a phenyl group attached directly or through an alkylene group, a phenyl-phenoxy group or an octyl group;

Cy is a phenyl group or a thiazole-phenyl group;

n is either 0 or 1;

R<sup>1</sup> and R<sup>2</sup> are hydrogen;

R<sup>3</sup> is selected from the group consisting of: (i) an alkyl group optionally substituted with an amino group, or and (ii) a cyclopentyl group, a cyclohexyl group, a phenyl group, or a pyridyl group, attached directly or through an alkylene group or an oxo group, and optionally substituted with a cyano group or a fluoromethyl group;

R<sup>4</sup> and R<sup>5</sup> are each independently from each other selected from the group consisting of H, OH, COOH, and OCH<sub>2</sub>COOH;

to the subject in an amount sufficient to treat-or prevent the at least one disease type II diabetes or obesity.

## Claim 2-9 (Cancelled)

Claim 10 (Currently Amended): An aryl dicarboxamide according to any of formulae (Ia), (Ib) or (Ic):

HO 
$$(Ia)$$
  $(Ib)$   $(Ic)$ 

wherein

A is an aminocarbonyl moiety of the formula -CO-NHR<sup>6</sup> wherein R<sup>6</sup> is a phenyl group attached directly or through an alkylene group, a phenyl-phenoxy group, or an octyl group;

Cy is a phenyl group or a thiazole-phenyl group;

n is either 0 or 1;

R<sup>1</sup> and R<sup>2</sup> are hydrogen;

R<sup>3</sup> is selected from the group consisting of: (i) an alkyl group optionally substituted with an amino group, or-and (ii) a cyclopentyl group, a cyclohexyl group, a phenyl group, or a pyridyl group, attached directly or through an alkylene group or an oxo group, and optionally substituted with a cyano group or a fluoromethyl group.

Claim 11 (Currently Amended): An aryl dicarboxamide according to formula (Ib) or (Ic):

$$HO_2C$$
 $HO_2C$ 
 $HO_2$ 

wherein

A is an aminocarbonyl moiety of the formula –CO-NHR<sup>6</sup> wherein R<sup>6</sup> a phenyl group attached directly or through an alkylene group, a phenyl-phenoxy group, or an octyl group;

Cy is a phenyl group or a thiazolyl-phenyl group;

n is either 0 or 1;

R<sup>1</sup> and R<sup>2</sup> are hydrogen;

R<sup>3</sup> is selected from the group consisting of:(i) an alkyl group optionally substituted with an amino group, or and (ii) a cyclopentyl group, a cyclohexyl group, a phenyl group, or a pyridyl group, attached directly or through an alkylene group or an oxo group, and optionally substituted with a cyano group or a fluoromethyl group.

Claims 12-14 (Cancelled)

Claim 15 (Previously Presented): An aryl dicarboxamide selected from the group consisting of:

5-[(3-cyclopentylpropanoyl)(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)amino]-2-hydroxybenzoic acid;

5-[(3-cyclopentylpropanoyl)(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)amino]-2-hydroxybenzoic acid;

 $[4-(\{\{[2-(4-\{[(4-pentylbenzyl)amino]carbonyl\}phenyl)-1,3-thiazol-4-yl]methyl\}-[(2E)-3-phenylprop-2-enoyl]amino\}methyl)phenoxy]acetic acid;$ 

5-[(3-cyclopentylpropanoyl)(4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)amino]-2-hydroxybenzoic acid;

2-hydroxy-5-{(4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)[4-(trifluoromethyl)-benzoyl]amino}benzoic acid;

2-hydroxy-5-[[(4-{[(4-phenoxybenzyl)amino]carbonyl}-1,3-thiazol-2-yl)methyl](3-phenylpropanoyl)amino]benzoic acid;

5-{benzoyl[(4-{[(4-phenoxybenzyl)amino]carbonyl}-1,3-thiazol-2-yl)methyl]-amino}-2-hydroxybenzoic acid;

2-hydroxy-5-{[(4-{[(4-phenoxybenzyl)amino]carbonyl}-1,3-thiazol-2-yl)methyl][4-(trifluoromethyl)benzoyl]amino}benzoic acid;

5-[(cyclohexylcarbonyl)(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)amino]-2-hydroxybenzoic acid;

2-hydroxy-5-[(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)(3-phenylpropanoyl)-amino]benzoic acid;

5-[benzoyl(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)amino]-2-hydroxybenzoic acid;

5-[acetyl(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)amino]-2-hydroxybenzoic acid;

5-[(4-cyanobenzoyl)(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)amino]-2-hydroxybenzoic acid;

Reply to final Office Action of September 20, 2007

2-hydroxy-5-[(phenoxyacetyl)(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)-amino]-benzoic acid;

2-hydroxy-5-{(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)[4-(trifluoromethyl)-benzoyl]amino}benzoic acid;

2-hydroxy-5-{(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)[(2*E*)-3-phenylprop-2-enoyl]amino}benzoic acid;

5-[(N,N-dimethylglycyl)(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)amino]-2-hydroxybenzoic acid;

2-hydroxy-5-[(3-methylbut-2-enoyl)(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)-amino]benzoic acid;

2-hydroxy-5-{[{4-[(octylamino)carbonyl]benzyl}(phenoxyacetyl)amino]methyl}-benzoic acid;

2-hydroxy-5-({{4-[(octylamino)carbonyl]benzyl}[4-(trifluoromethyl)benzoyl]-amino}methyl)benzoic acid;

2-hydroxy-5-({{4-[(octylamino)carbonyl]benzyl}[(2E)-3-phenylprop-2-enoyl]-amino}methyl)benzoic acid;

5-{[(3-cyclopentylpropanoyl)(4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)-amino]methyl}-2-hydroxybenzoic acid;

2-hydroxy-5-{[(4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)(phenoxyacetyl)-amino]methyl}benzoic acid;

2-hydroxy-5-({(4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)[4-(trifluoromethyl)-benzoyl]amino}methyl)benzoic acid;

2-hydroxy-5-{[(3-methylbut-2-enoyl)(4-{[(4-pentylbenzyl)amino]carbonyl}-benzyl)amino]methyl}benzoic acid;

5-{[(3-cyclopentylpropanoyl)(4-{[(4-phenylbutyl)amino]carbonyl}benzyl)-amino]methyl}-2-hydroxybenzoic acid;

 $2-hydroxy-5-(\{[(4-\{[(4-pentylbenzyl)amino]carbonyl\}-1,3-thiazol-2-yl)methyl][(2E)-3-phenylprop-2-enoyl]amino\}methyl)benzoic acid;$ 

[4-({(4-{[(4-phenoxybenzyl)amino]carbonyl}benzyl)[4-(trifluoromethyl)benzoyl]-amino}methyl)phenoxy]acetic acid;

2-hydroxy-5-[(4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)(3-phenylpropanoyl)-amino]benzoic acid;

4-[(3-cyclopentylpropanoyl)(4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)amino]-2-hydroxybenzoic acid;

2-hydroxy-4-{(4-{[(4-pentylbenzyl)amino]carbonyl}benzyl)[4-(trifluoromethyl)-benzoyl]amino}benzoic acid;

2-hydroxy-5-[{[2-(4-{[(4-pentylbenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}(phenoxyacetyl)amino]benzoic acid;

2-hydroxy-5-{{[2-(4-{[(4-pentylbenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}[4-(trifluoromethyl)benzoyl]amino}benzoic acid;

5-([(6-chloropyridin-3-yl)carbonyl]{[2-(4-{[(4-pentylbenzyl)amino]carbonyl}-phenyl)-1,3-thiazol-4-yl]methyl}amino)-2-hydroxybenzoic acid;

5-((4-cyanobenzoyl){[2-(4-{[(4-pentylbenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}amino)-2-hydroxybenzoic acid;

2-hydroxy-5-((3-methylbut-2-enoyl){[2-(4-{[(4-pentylbenzyl)amino]carbonyl}-phenyl)-1,3-thiazol-4-yl]methyl}amino)benzoic acid;

5-((3-cyclopentylpropanoyl){[2-(4-{[(4-phenoxybenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}amino)-2-hydroxybenzoic acid;

2-hydroxy-5-{{[2-(4-{[(4-phenoxybenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}[4-(trifluoromethyl)benzoyl]amino}benzoic acid;

2-hydroxy-5-[{[2-(4-{[(4-phenoxybenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}(3-phenylpropanoyl)amino]benzoic acid;

5-(benzoyl{[2-(4-{[(4-phenoxybenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}amino)-2-hydroxybenzoic acid;

[4-({{[2-(4-{[(4-pentylbenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}[4-(trifluoromethyl)benzoyl]amino}methyl)phenoxy]acetic acid;

(4-{[{[2-(4-{[(4-pentylbenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}(3-phenylpropanoyl)amino]methyl}phenoxy)acetic acid;

[4-({{[2-(4-{[(4-phenylbutyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}[4-(trifluoromethyl)benzoyl]amino}methyl)phenoxy]acetic acid;

(4-{[{[2-(4-{[(4-phenylbutyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}(3-phenylpropanoyl)amino]methyl}phenoxy)acetic acid;

 $[4-(\{\{[2-(4-\{[(4-phenylbutyl)amino]carbonyl\}phenyl)-1,3-thiazol-4-yl]methyl\}[(2E)-3-phenylprop-2-enoyl]amino\}methyl)phenoxy]acetic acid;$ 

 $\{4-[((N,N-dimethylglycyl)\{[2-(4-\{[(4-phenylbutyl)amino]carbonyl\}phenyl)-1,3-thiazol-4-yl]methyl\}amino)methyl]phenoxy\}acetic acid;$ 

{4-[((cyclohexylcarbonyl){[2-(4-{[(4-phenylbutyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}amino)methyl]phenoxy}acetic acid;

{4-[((phenoxyacetyl){[2-(4-{[(4-phenoxybenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}amino)methyl]phenoxy}acetic acid;

[4-({{[2-(4-{[(4-phenoxybenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}[4-(trifluoromethyl)benzoyl]amino}methyl)phenoxy]acetic acid;

(4-{[{[2-(4-{[(4-phenoxybenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}(3-phenylpropanoyl)amino]methyl}phenoxy)acetic acid;

{4-[((cyclohexylcarbonyl){[2-(4-{[(4-phenoxybenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}amino)methyl]phenoxy}acetic acid;

[4-({[(2-{4-[(octylamino)carbonyl]phenyl}-1,3-thiazol-4-yl)methyl][4-(trifluoromethyl)benzoyl]amino}methyl)phenoxy]acetic acid; and

(4-{[[(2-{4-[(octylamino)carbonyl]phenyl}-1,3-thiazol-4-yl)methyl](3-phenylpropanoyl)amino]methyl}phenoxy)acetic acid.

Claim 16 (Previously Presented): A pharmaceutical composition comprising at least one aryl dicarboxamide according to claim 11 and a pharmaceutically acceptable carrier, diluent, excipient, or combination thereof.

Claim 17 (Previously Presented): A pharmaceutical composition comprising at least one aryl dicarboxamide according to claim 10 and a pharmaceutically acceptable carrier, diluent, excipient, or combination thereof.

Claim 18 (Currently Amended): A method of preparing the aryl dicarboxamide of formula (I), comprising deprotecting, transforming, or deprotecting and transforming (I') to form the aryl dicarboxamide (Ia):

$$R^{4} \xrightarrow{R^{5}}$$

$$R^{1} \xrightarrow{N} R^{3}$$

$$R^{2} \xrightarrow{Cy} O$$

$$FG$$
(I')

Application No. 10/565,557

Reply to final Office Action of September 20, 2007

wherein FG is A or a leaving group,

wherein:

A is an aminocarbonyl moiety of the formula -CO-NHR<sup>6</sup>, wherein R<sup>6</sup> is a phenyl group attached directly or through an alkylene group, a phenyl-phenoxy group, or an octyl group;

Cy is a phenyl group or a thiazole-phenyl group;

n is either 0 or 1;

R<sup>1</sup> and R<sup>2</sup> are hydrogen;

R<sup>3</sup> is selected from the group consisting of:(i) an alkyl group optionally substituted with an amino group, or-and (ii) a cyclopentyl group, a cyclohexyl group, a phenyl group, or a pyridyl group, attached directly or through an alkylene group or an oxo group, and optionally substituted with a cyano group or a fluoromethyl group; and

 $R^4$  and  $R^5$  are each independently from each other selected from the group consisting of H, OH, COOH, and OCH<sub>2</sub>COOH.

Claims 19-28 (Cancelled)